Many cellular structures are assembled from networks of actin filaments, and the architecture of these networks depends on the mechanism by which the filaments are formed. Several classes of proteins are known to assemble new filaments, including the Arp2/3 complex, which creates branched filament networks, and Spire, which creates unbranched filaments 1,2 . We find that JMY, a vertebrate protein first identified as a transcriptional co-activator of p53, combines these two nucleating activities by both activating Arp2/3 and assembling filaments directly using a Spire-like mechanism. Increased levels of JMY expression enhance motility, whereas loss of JMY slows cell migration. When slowly migrating HL-60 cells are differentiated into highly motile neutrophil-like cells, JMY moves from the nucleus to the cytoplasm and is concentrated at the leading edge. Thus, JMY represents a new class of multifunctional actin assembly factor whose activity is regulated, at least in part, by sequestration in the nucleus.
By searching genome databases for sequences related to the Wiskott-Aldrich syndrome protein (WASp) Homology 2 (WH2) domain we discovered a potential Arp2/3-activating sequence, WWWCA, in the vertebrate protein JMY (Fig. 1a ). This sequence is composed of three tandem repeats of the actin-monomer-binding WH2 domain (WWW), a central domain (C) that binds actin and Arp2/3, and an Arp2/3-binding acidic domain (A). These sequence elements, first identified in WASpfamily proteins 1, 3 , collaborate in activating Arp2/3. The identification of these elements in JMY was surprising, because JMY localizes primarily to the nucleus and was originally discovered as a binding partner of p300, a co-activator for many transcription factors, including the tumour suppressor p53 (ref. 4) . In fibroblasts JMY accumulates in the nucleus in response to DNA damage, where it enhances the p53-dependent transcription of pro-apoptotic genes 4, 5 .
To determine whether JMY also has a function in the assembly of the actin cytoskeleton, we tested the effect of JMY expression on actin organization in vivo. Overexpression of JMY in human U2OS cells induces the formation of elongated actin filament structures that co-localize with JMY ( Fig. 1b) , in a similar manner to overexpression of WASp-family proteins and the actin nucleation factor Spire 2,6 . Truncation mutants demonstrate that the WH2 cluster is required for this effect but, curiously, the Arp2/3-binding CA domain is not ( Supplementary Information, Fig. S1 ). Expression of the carboxy-terminal region of JMY fused to green fluorescent protein (GFP-PWWWCA) produces a linear, dose-dependent increase in the cellular concentration of filamentous actin (Fig. 1c) as judged by correlating Alexa Fluor 568-phalloidin staining with GFP fluorescence (n = 457; Fig. 1d ). In contrast, expressing GFP alone has no significant effect on cellular levels of filamentous actin (n = 458; Fig. 1d ; Supplementary Information, Fig. S1 ).
To study how JMY affects actin assembly in vitro, we first verified that all three putative WH2 domains (W a , W b and W c , from amino terminus to carboxy terminus) bind monomeric actin ( Supplementary  Information, Fig. S2 ). JMY activates Arp2/3 in vitro, as determined by pyrene-actin polymerization assays using a C-terminal fragment of JMY (WWWCA) ( Fig. 1e ; t 1/2 (JMY + actin + Arp2/3) = 42.2 ± 2.3 s, versus t 1/2 (actin + Arp2/3) = 1,193 ± 28 s (mean ± s.e.m.). JMY WWWCA also induces rapid actin polymerization in the absence of Arp2/3 ( Fig. 1e ; t 1/2 = 188.5 ± 4.4 s). The JMY-dependent increase in polymerization rate is dose-dependent, both with and without Arp2/3 (Fig. 1f ). This result is quite surprising and distinguishes JMY from all other proteins known to activate Arp2/3. N-WASp WWCA, for example, activates Arp2/3 to a similar extent as JMY but does not accelerate polymerization in the absence of Arp2/3 (Fig. 1e ).
By itself JMY could accelerate actin assembly by nucleating new filaments, by increasing the rate of filament elongation, or by severing existing filaments to create new barbed ends 2, 7 . JMY does not affect the elongation of preformed filaments, arguing that it neither accelerates elongation nor severs, but rather nucleates new filaments ( Supplementary Information, Fig. S3a-c) . Indeed, we observe more than 12-fold more filaments in the presence of JMY WWWCA compared with actin alone (Fig. 2a, b ). In the presence of Arp2/3, JMY WWWCA produces branched filaments, which is consistent with nucleation by Arp2/3 (Fig. 2c, left panel) , whereas, by itself, JMY nucleates unbranched filaments ( Fig. 2a ). In assembly reactions, filament length is inversely l e t t e r s (a) Domain structure of JMY. The C terminus of JMY is homologous to activators of Arp2/3. A poly-proline (P) domain 28 proportional to the rate of nucleation, and filaments made in the presence of JMY are shorter than those made with actin alone. Arp2/3nucleated filaments are even shorter ( Fig. 2d ). JMY produces twice as many branches per micrometre as Scar1/WAVE1 ( Fig. 2e ), which is consistent with JMY inducing a faster rate of Arp2/3 activation than Scar. Some proteins that cap barbed ends in vivo (for example capping protein) nucleate filaments that elongate from their pointed end in vitro 8 .
To determine whether JMY caps barbed ends, we made filaments and depolymerized them in the presence of JMY WWCA. JMY does not inhibit disassembly, arguing that it does not cap barbed ends but instead promotes polymerization by nucleating new filaments that elongate from their barbed ends ( Supplementary Information, Fig. S3d, e ). Direct nucleation seems to explain the unexpected ability of JMY to induce actin assembly in vivo in the absence of the Arp2/3-binding CA domain ( Supplementary Information, Fig. S1 ).
We proposed that, in a similar manner to Spire 2 , JMY uses its tandem WH2 domains to nucleate new filaments. We tested the activity of constructs consisting of either all three WH2 domains (JMY WWW) or the two C-terminal WH2 domains (JMY W b W c ). JMY WWW nucleates actin as well as WWWCA, indicating that the CA region has no function in direct nucleation ( Fig. 2f ). Moreover, addition of Arp2/3 to JMY WWW does not further increase the rate of polymerization ( Fig. 2f ). As with Spire, the two C-terminal WH2 domains (JMY W b W c ) are sufficient for nucleation, but all three JMY WH2 domains are required for maximal activity ( Supplementary Information, Fig. S3h, i) .
In contrast, a fragment composed of a single WH2 domain (W c ) and the CA domains (JMY WCA) activates Arp2/3 but does not nucleate filaments on its own ( Fig. 2g ). JMY contains a conserved tryptophan residue known to be important for Arp2/3 binding in all WASp-family proteins 9 . Replacing this tryptophan residue with alanine in JMY decreases the activation of Arp2/3 without affecting intrinsic nucleation activity ( Supplementary Information, Fig. S3j ). These results suggest that nucleation and Arp2/3 activation are separable activities, and that JMY activates Arp2/3 by the same mechanism as WASp-family proteins.
Similarities in the sequences and activities of JMY and Spire suggested that the two proteins nucleate filaments by a common mechanism. We compared the kinetics of nucleation by JMY and Spire over a range of actin concentrations. At all concentrations of actin tested, JMY and Spire had nearly identical kinetics ( Supplementary Information, Fig. S3k , l). In addition, similarly to Spire, high concentrations of JMY sequester actin monomers ( Supplementary Information, Fig. S3m , n). Unlike Spire, however, JMY WWCA does not prevent the dissociation of monomers from the pointed end of filaments (Supplementary Information, Fig. S3f , g). It is possible that the full-length JMY interacts with filament ends, but this is not required for nucleation.
Spire nucleates actin by stitching monomers together with tandem WH2 domains and a novel actin-binding motif (previously called Linker 3; ref.
2) that we designate the monomer binding linker (MBL). Spire-MBL, a short (about 15-residue) sequence connecting the third and fourth WH2 domains, is sufficient to promote weak nucleation 2 . We compared the sequences of Spire-MBL with the region between the two C-terminal WH2 domains of JMY (W b and W c ) and N-WASp. Most residues conserved between Spire homologues are also conserved in JMY, but not in N-WASp ( Fig. 3a) . Another WH2-containing nucleation factor, Cordon Bleu (Cobl), is thought to operate by a different mechanism 10 ; consistent with this was the fact that we saw no conservation between the linker regions of Cobl and Spire (Fig. 3a) .
Do JMY and Spire nucleate actin by the same mechanism? We replaced the JMY linker with a set of glycine-serine repeats (JMY W b W c (gs5)) and compared it with a similar Spire mutant (Spire CD(gs5)). JMY W b W c (gs5) has a modest defect in nucleation, whereas replacing the linker in Spire has a more pronounced effect ( Fig. 3b, d ; Supplementary Information, Fig. S3o ). Interestingly, inserting either the JMY-MBL or Spire-MBL between the N-WASp WH2 domains (NW WJW or WSW) converted N-WASp into a nucleator ( Fig. 3c, d ; Supplementary Information, Fig. S3p ), whereas inserting a flexible linker (NW WW(gs5)) did not ( Fig. 3b, d) . NW WJW and WSW do not nucleate as well as JMY or Spire. Thus, nucleation by JMY and Spire requires unique properties of both the linker (MBL) and the WH2 domains ( Fig. 3e ).
To investigate its role in actin assembly in vivo, we determined the localization of JMY in multiple cell types. JMY is primarily nuclear in mouse embryonic fibroblasts, B16-F10 mouse melanoma cells, NIH 3T3 cells and primary rat neurons (Supplementary Information, Fig. S4 , and data not shown). In ruffling B16-F10 cells, we observed a small fraction of JMY co-localized with actin filaments at the leading edge ( Supplementary Information, Fig. S4b ). In highly motile, primary human neutrophils, JMY was almost entirely excluded from the nucleus and co-localized with filaments at the leading edge ( Fig. 4d ). JMY does not bind actin filaments in vitro, so this localization does not simply reflect the direct interaction of JMY with filaments ( Supplementary  Information, Fig. S4d ).
Our localization studies suggest that the presence of JMY at the leading edge correlates with motility. To test this further, we investigated JMY expression and localization in HL-60 cells, which can exist as nonmotile, relatively undifferentiated cells or be induced to differentiate into highly motile cells 11 . In undifferentiated HL-60 cells, JMY is primarily nuclear and does not co-localize with filaments (primarily nuclear in 91% of cells, n = 246; Fig. 4a ; Supplementary Information, Fig. 5 ). The addition of 1.3% dimethylsulphoxide (DMSO) to the culture medium induces differentiation into highly motile cells that polarize and undergo chemotaxis. During differentiation, JMY localization shifts markedly, becoming almost entirely cytoplasmic. This shift occurs about two days before cells are competent to polarize in response to formyl peptide chemoattractant (fMLP; Supplementary Information, Fig. S5c ). In differentiated cells, JMY co-localizes with filamentous actin in the cell cortex (cytoplasmic in 94%, nuclear in 6%, n = 212; Fig. 4b ), and on addition of fMLP, JMY localizes strongly to the leading edge, where it overlaps with filamentous actin (88% of polarized cells, n = 311; Fig. 4c ; Supplementary Information, Fig. S5d ). A comparison of JMY staining with the location of soluble GFP in polarized cells shows that enrichment of JMY at the leading edge is not a volume artefact (Supplementary Information, Fig. S5e -g). These data suggest that translocation of JMY to the cytosol has a function in building the leading edge. Interestingly, expression of JMY's nuclear binding partner p300 disappears when HL-60 cells are differentiated, suggesting that the nuclear (p300/p53dependent transcription) and cytoplasmic (actin nucleation) roles of JMY are regulated by separate pathways (Fig. 4e ).
To examine the role of JMY in cell motility, we stably expressed GFP-JMY and GFP-JMY∆CA in U2OS cells, grew monolayers, scratched them, and monitored wound healing over time 12 . Cells expressing GFP-JMY migrated 17% faster than wild-type cells (n = 3; l e t t e r s Actin polymerization is as fast with WWW as it is with WWWCA. WWW lacks the Arp2/3-binding CA domain, so adding Arp2/3 to WWW does not accelerate polymerization over WWW alone. N-WASp WW does not nucleate actin. (g) JMY WCA is sufficient to activate Arp2/3 but does not nucleate actin. The rate of actin polymerization in the presence of JMY WCA and Arp2/3 is similar to reactions containing Scar WCA and Arp2/3. In the absence of Arp2/3, JMY WCA has no effect on actin polymerization. Experimental conditions were as in Fig. 1 . P < 0.003; Fig. 5a , b; Supplementary Information, Fig. S6 ). In contrast, cells expressing GFP-JMY∆CA migrated at the same rate as wild-type cells (GFP-JMY, 43.8 ± 1.6 µm h −1 ; GFP-JMY∆CA, 38.5 ± 1.7 µm h −1 ; wild-type, 37.5 ± 1.0 µm h −1 ), suggesting that JMY requires its Arp2/3activating activity to enhance motility. We next knocked down JMY expression in cultured U2OS and HEK 293 cells by RNA-mediated interference (RNAi). Western blotting shows that RNAi was efficient ( Fig. 5e ; Supplementary Information,  Fig. S6 ). In both cell lines, knockdown of JMY expression significantly slows the rate of wound healing ( Fig. 5c, d ; Supplementary  Information, Fig. S6 ). In the first 6 h, cells treated with JMY small interfering RNA (siRNA) moved 38.0% more slowly than control U2OS cells (n = 4; P < 0.05). By 24 h, control cells migrated fully into the wound, whereas cells treated with JMY siRNA migrated only 86% of the distance (Fig. 5a, b ; n = 4). Control HEK 293 cells migrated 92% of the distance by 24 h, in contrast with 60% for cells treated with JMY siRNA ( Supplementary Information, Fig. S6 ; n = 7).
Defects in wound healing could be caused by (1) reduced actin assembly, (2) altered transcription, (3) reduced cell division or increased apoptosis, or (4) off-target effects of the siRNA. Consistent with the first explanation was our observation that that JMY knockdown cells contained 11.4 ± 0.4% (n = 396, P < 0.03) less filamentous actin than wild-type cells ( Fig. 5f ). Loss of either p53 or p300, both of which are required for all JMY's known transcriptional effects, leads to increased cell migration [13] [14] [15] , which is inconsistent with transcriptional effects on motility. In addition, less than 5% of cells close to the wound divide in the first 6 h of the assay, making it unlikely that cell division contributes to the observed defect. Knockdown of JMY was shown to decrease apoptosis 5 , ruling out the third explanation. To address possible offtarget effects, we used three different siRNAs, from different regions of the human JMY gene, to knock down expression in HEK 293 cells. All three caused migration defects ( Supplementary Information, Fig. S6g ), whereas a control siRNA had no effect. We next tested whether JMY localizes to the leading edge of U2OS cells during migration in response to a wound, as seen in highly motile HL-60 cells. We fixed and stained U2OS cells 15 min after wounding, as well as cells in subconfluent and non-wounded cultures. Although most of JMY was nuclear in these cells, we also observed both endogenous JMY and GFP-JMY co-localized with filamentous actin at the leading edge ( Fig. 5g ; Supplementary Information, Fig. S4c ), both in cells adjacent to a wound and in ruffling edges of subconfluent cells (data not shown). Thus, even in cells in which JMY is predominantly nuclear, a fraction of the protein can influence actin assembly at the leading edge and promote migration.
JMY combines an unusual set of activities. The combination of transcriptional co-activation and actin nucleation activities suggests that JMY might mediate cellular decisions involving apoptosis and migration. Alternatively, JMY might be a chimaera whose transcriptional and cytoskeletal functions are more or less independent. More intriguing is JMY's combination of Arp2/3-dependent and Arp2/3-independent nucleation activities. A cell switching from a resting to a motile state must remodel its cytoskeleton extensively 16 . The leading edge of most migrating cells is characterized by a highly branched dendritic arbour of actin filaments nucleated by Arp2/3, and one requirement for generating such a network is the pre-existence of 'mother' filaments for Arp2/3 to bind and branch from 17, 18 . Although resting cells contain some actin filaments (such as cortical actin or stress fibres), recent work suggests that not all filaments can serve as efficient substrates for Arp2/3-dependent nucleation 19, 20 . We propose that JMY contributes to cell motility by nucleating filaments to jump-start Arp2/3-dependent nucleation and branching. By first nucleating new mother filaments and then activating Arp2/3 to branch off these filaments, JMY could promote the rapid formation of a branched actin network. It is also possible that JMY has evolved to promote actin polymerization in different cellular contexts, either in the cytoplasm in the presence of Arp2/3, or in the nucleus in the absence of Arp2/3 (see model in Fig. 5h ). For example, it would be interesting to test whether inactivation of JMY's function in actin dynamics affects its role as a p300-dependent transcriptional co-activator for p53. Future work is aimed at testing these models.
MeTHodS
Molecular biology and biochemistry. Constructs were cloned from full-length mouse JMY 4 , fly Spire 2 and rat N-WASp, with standard techniques. Primer sequences are available from the authors on request. All constructs were sequenced to ensure that no mutations were introduced during cloning. JMY fragments were expressed as glutathione S-transferase (GST) fusions in Escherichia coli and purified with a combination of glutathione and cation chromatography. Except for individual WH2 domains ( Supplementary Information, Fig. S2 ), the GST was removed to prevent dimerization of the recombinant protein, which results in a marked increase in the rate of both intrinsic nucleation and activation of Arp2/3 (data not shown). To improve the reproducibility of fluorimetry reactions, we mutated the non-conserved cysteine C978 to serine. This mutation does not change the kinetics of activation of Arp2/3 ( Supplementary Information, Fig. S6h , i) but results in a peptide that is more stable than the wild type. JMY concentrations were calculated form predicted molar extinction coefficients for JMY peptides that contained tryptophan residues (ProtParam), or by quantitative SDS-PAGE and staining with Sypro-Red (Invitrogen).
Actin polymerization assays. Actin was purified from Acanthamoeba castellani as described 21 , labelled with pyrene iodoacetamide as described 22 , and stored on ice. Arp2/3 was purified from Acanthamoeba as described 23 and flash-frozen with 10% glycerol. For all assays, Arp2/3 was thawed daily and diluted with 1 mg ml −1 BSA in buffer A (0.2 mM ATP, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), 0.1 mM CaCl 2 , 0.02% w/v sodium azide, 2 mM Tris-HCl pH 8.0 at 4 °C). Actin polymerization assays were performed in 1 × KMEI (50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 10 mM imidazole pH 7.0). Ca 2+ -actin was converted into Mg 2+ -actin by incubating actin in 50 mM MgCl 2 , 0.2 mM EGTA for 2 min before adding 10 × KMEI and test components. Pyrene fluorescence was measured with an ISS PCI/K2 fluorimeter. Unless otherwise noted, polymerization reactions contained 2 µM actin (labelled with 5% pyrene), 2.5 nM Arp2/3 and 167 nM JMY or N-WASp. JMY proteins were diluted with 10 mg ml −1 BSA in buffer A to prevent loss of activity. To normalize fluorimetry data, we subtracted the offset from zero then divided by the plateau value of actin alone, so as to not mask the effects of sequestration by JMY. For halftime calculations, reactions were normalized by dividing by their own plateau and solving for time at half-maximal fluorescence (0.5 arbitrary units).
To reveal actin filaments we polymerized 2 µM actin under the same conditions as those used for fluorimetry, then arrested reactions at the times indicated with Alexa Fluor 488 phalloidin and Latrunculin B. This technique preserves the ratio of monomeric actin to filamentous actin at the moment of quenching 24 . To keep the concentration of F-actin constant we arrested reactions at their individual t 9/10 (time at nine-tenths-maximal fluoresence, 0.9 arbitrary units) values: 1 min 40 s for JMY + Arp2/3, 6 min 20 s for Scar + Arp2/3, and 37 min 0 s for actin alone. Filaments were diluted to low nanomolar concentrations and spotted onto coverslips coated with poly-(l-lysine) (Sigma), using wide-bore pipette tips to minimize shearing.
Cell culture. U2OS (ATCC) and HEK 293 cells were cultured in DMEM medium supplemented with 10% FBS, 2 mM l-glutamine, non-essential amino acids, and penicillin-streptomycin (UCSF Cell Culture facility). For transfection, cells were seeded onto glass coverslips and transfected with haemagglutinin-tagged JMY 4 using GeneJuice (Merck), or with GFP-JMY and GFP-RNAi constructs using Lipofectamine LTX (Invitrogen), in accordance with the manufacturer's protocol. HL-60 cells were cultured as described 25 , in RPMI-1640 with 25 mM HEPES, 2.0 g l −1 NaHCO 3 , 10% FBS, 1% antibiotic-antimycotic (Fisher), and were passaged every three or four days to a density of 2 × 10 5 cells ml −1 . Differentiation was in complete medium containing 1.3% DMSO (Hybrimax; Sigma). All cells were grown at 37 °C with 5% CO 2 . Primary human neutrophils were obtained by finger pinprick as described 26 .
Immunofluorescence of HL-60 cells was performed as described 25 . In brief, flamed coverslips were treated with 200 µg ml −1 bovine plasma fibronectin (Sigma) in PBS, washed with PBS, and blocked with 1.8% low-endotoxin BSA (Sigma) in modified Hanks buffered saline solution (mHBSS: 150 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 10 mM glucose, 20 mM HEPES pH 7.4 at 22 °C) for 5 min before adhering cells. Cells were pelleted and resuspended in BSA/mHBSS, adhered to coverslips for 30-60 min at 37 °C, and then washed to remove unbound cells. Stimulation or mock stimulation was in BSA/mHBSS with 100 nM (HL-60s) or 20 nM (human neutrophils) fMLP, or DMSO (carrier), for 5 min at 22 °C. Cells were fixed in 3.2% formaldehyde in cytoskeletal buffer (138 mM KCl, 3 mM MgCl 2 , 2 mM EGTA, 320 mM sucrose, 10 mM HEPES pH 7.2 at 22 °C). For immunofluorescence of U2OS cells, cells were plated on flamed, fibronectincoated coverslips, and fixed for 30 min in 3.2% formaldehyde in PBS. Cells were then permeabilized with 0.1% Triton X-100 in PBS with 1.4 U ml −1 Alexa Fluor 568-phalloidin (Invitrogen) to stabilize and reveal filaments. For JMY immunolocalization, rabbit polyclonal JMY antibody 1289 (ref. 5) or anti-haemagglutinin antibody HA11 (Babco) was used at 1:500 dilution. Alexa Fluor 488-labelled goat anti-rabbit secondary antobody (Invitrogen) was used at 1:500 dilution. 4,6-Diamidino-2-phenylindole (DAPI; Sigma) was used at 0.5 µg ml −1 . Samples were mounted with fluorescent mounting medium (DakoCytomation).
Epifluorescence and wide-field images were acquired on a Nikon TE300 inverted microscope equipped with a Hamamatsu C4742-98 cooled chargecoupled device camera, with Simple PCI software (Compix), using 100× and 60× 1.4 numerical aperture (NA) Plan Apo objectives (Nikon), or with a 10× 0.6 NA phase objective, using MicroManager software 27 . For quantification of F-actin levels in cells expressing GFP-PWWWCA or GFP, micrographs were acquired with an IX Micro automated microscope, using identical illumination conditions. Cells were identified and outlined by using ImageJ software, background was subtracted, and the average intensities in the red and green channels were measured. We used ImageJ (National Institutes of Health) and Adobe Photoshop (Adobe) for image analysis and contrast adjustment.
For wound-healing experiments, cells were plated on marked coverslips at the same density, scratch-wounded with a micropipette tip, washed to removed detached cells, and then given fresh medium and kept at 37 °C during image acquisition. Stable lines of U2OS cells stably expressing GFP-JMY and variants were selected in 500 µg ml −1 G418 for at least three weeks, then enriched by fluorescence-activated cell sorting (FACS) (UCSF Flow Cytometry Core). siRNA was used at a final concentration of 25 nM (hJMY siRNA from Santa Cruz and control non-targeting 2 from Dharmacon) and transfected into cells with Oligofectamine or Dharmafect 1 (both in accordance with the manufacturer's protocols), and cells were grown for 72 h before experiments. To discriminate between cells treated with RNAi and cells not treated with RNAi, pL-UGIH plasmid (American Type Culture Collection) was modified to contain a human JMY-specific hairpin based on the sequence of JMY-specific siRNA-3 by the method of ref. 25 . HEK 293 cells transiently transfected with this construct were grown for seven days before fixation or immunoblotting.
Standard methods were used for western blotting, using 1:500 1289 or 1:1,000 L-16 (Santa Cruz Biotechnology) JMY primary antibodies and 1:5,000 horseradish peroxidase (HRP)-labelled anti-rabbit secondary antibodies (Jackson ImmunoResearch). p300-CT primary antibody (Millipore) was used at 1:500, goat anti-human glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz) was used at a dilution of 1:10,000, and mouse anti-human actin (Sigma) was used at 1:20,000. HRP-labelled secondary antibodies (Dako) were used at 1:10,000 dilution, and enhanced chemiluminescence reagent (SuperSignal West Pico; Pierce) was used in accordance with the manufacturer's instructions. All error values are s.e.m. We used two-tailed unpaired t-tests, assuming unequal variance, to calculate P values (Microsoft Excel). Conserved hydrophobic residues are highlighted gray, and conserved basic residues are highlighted red. JMY WH2 domains were identified by searching genome databases using a consensus WH2 domain sequence derived from a combination of sequence conservation, structural, and biochemical criteria. Fig. 1f ) and JMY WWCA. j, Conserved tryptophan in the JMY acidic domain in important for activating the Arp2/3 complex, but not for JMY's intrinsic nucleation. This is consistent with JMY activating the Arp2/3 complex by the same mechanism as WASp-family proteins, and agrees with our results using WWW and W b W c , which indicate that only JMY WH2 domains contribute to nucleation. Experimental conditions as in Fig. 1c. k- (Invitrogen) and quantified gels using a multiformat imager (Typhoon 9400, GE Healthcare) and ImageQuant software (GE Healthcare).
Depolymerization and critical concentration assays were performed as described 1 .
Briefly, for barbed end depolymerization, we polymerized 5 µM actin (40% pyrene labelled) for at least one hour. To stimulate depolymerization, we diluted these filaments tenfold (to 500 nM) in 1x KMEI containing the proteins to be tested. Depolymerization is due to filaments disassembling until they reach a new steady state. Under these conditions depolymerization proceeds both from the barbed and pointed ends but dissociation of monomers from the barbed end is roughly 25 times faster than from the pointed end (ADP actin) 3 . The depolymerization rate we measure is, therefore, mostly dependent on the kinetics of the barbed end.
For pointed-end depolymerization experiments we made gelsolin-actin seeds by mixing 24 µM actin, 12 µM gelsolin, and 10 mM CaCl2 in Buffer A and polymerizing for 4 hours at room temperature followed by incubation overnight at 4° C 4 . The concentration of pointed ends was quantified by actin elongation experiments. We made labelled filaments with capped barbed ends by polymerizing 5 µM actin (40% pyrene labelled) in the presence of 30 nM gelsolin-actin seeds. To stimulate depolymerization, we diluted these capped filaments tenfold (to 500 nM) in 1x KMEI containing proteins to be tested. To ensure that filament barbed ends were capped, we measured depolymerization kinetics in the presence of 500 nM Arp2/3, which caps free pointed ends.
Elongation experiments were performed as described. 1 Briefly, seeds were prepared by polymerizing 4 µM unlabeled actin in 1x KMEI for 1 hour at 22°C. 4 µM actin (5% pyrene labelled) was then polymerized alone or in the presence of these actin filament seeds, with or without 500 nM JMY WWCA (as noted). Polymerization rates were calculated during the linear phase of the reactions, between 40 and 180 s.
